Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE™ NHL-1 trial

David Soong, Isil Altintas, John Karavitis, Kim M. Linton, Wojciech Jurczak, Catherine Thieblemont, Kevin Zhao, Edith Szafer-Glusman, Daniela Hoehn, Elena Favaro, Mariana Sacchi, Maria Jure-Kunkel

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Article number5071
Number of pages2
JournalCancer Research
Volume84
Issue number6_Supplement
Early online date15 Mar 2024
DOIs
Publication statusPublished - 22 Mar 2024

Cite this